Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Graham Marshman who wrote (62)	11/20/1997 9:26:00 AM
From: Graham Marshman	Read Replies (1) \| Respond to of 4028

I've been comparing this with Geron. Maybe those of you who've been involved longer can help out, but my understanding of Geron is as below: Geron is focused at compounds that inhibit telomerase in their cancer thrust - similar for anti-aging. This work is in pre-clinical stage. Company has 7 patents issued, one that may be a CYGS problem relating to cancer and telomerase. Recent "mouse" work has taken some of the hype off telomerase inhibition as the cancer cure-all. They have substantial revenue coming in from collaboration and grants. Geron's market cap is $90M approx. CYGS focus is on telomere lengthening via vector delivery. Telomerase reduction appears to be a side effect of this. Two patents applied for, none granted to date. Work is in pre-clinical state. There is some (?) revenue from collaboration. Market cap is $6M approx (?) Comments appreciated, Graham